Abstract:During the past quarter century, the diagnosis and treatment of cystic fibrosis (CF) have been transformed by molecular sciences that initiated a new era with discovery of the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene. The knowledge gained from that breakthrough has had dramatic clinical impact. Although once a diagnostic dilemma with long delays, preventable deaths, and irreversible pathology, CF can now be routinely diagnosed shortly after birth through newborn screening programs. This strategy of pre-symptomatic identification has eliminated the common diagnostic "odyssey" that was a failure of the healthcare delivery system causing psychologically traumatic experiences for parents. Therapeutic advances of many kinds have culminated in CFTR modulator treatment that can reduce the effects of or even correct the molecular defect in the chloride channel —the basic cause of CF. This astonishing advance has transformed CF care as described fully herein. Despite this impressive progress, there are challenges and controversies in the delivery of care. Issues include how best to achieve high sensitivity newborn screening with acceptable specificity; what course of action is appropriate for children who are identified through the unavoidable incidental findings of screening tests (CFSPID/CRMS cases and heterozygote carriers); how best to ensure genetic counseling; when to initiate the very expensive but life-saving CFTR modulator drugs; how to identify new CFTR modulator drugs for patients with non-responsive CFTR variants; how to adjust other therapeutic modalities; and how to best partner with primary care clinicians. Progress always brings new challenges, and this has been evident worldwide for CF. Consequently, this article summarizes the major advances of recent years along with controversies and describes their implications with an international perspective.

Postexercise skeletal muscle glucose transport is normal in kininogen-deficient rats.

Improving gastrointestinal health in children and young people with cystic fibrosis

Improving growth in infants with CF

Evaluation of Growth and Changes in Body Composition Following Neonatal Diagnosis of Cystic Fibrosis

Super-Stable Superconducting MRI Magnet Operating for 25 Years

Advances in the restoration of CFTR in children and pwCF with "mild disease"

Analysis of differential sensitivities of synchronized HeLa S3 cells to radiations and chemical carcinogen during the cell cycle. II. Ultraviolet light.

Evolution of nutritional management in children with cystic fibrosis – a narrative review

New drugs, new challenges in cystic fibrosis care

What the future holds: cystic fibrosis and aging

Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians

Clinical outcomes at 9–10 years of age in children born with cystic fibrosis transmembrane conductance regulator related metabolic syndrome

Association Between Practice Patterns and Body Mass Index Percentile in Infants and Young Children with Cystic Fibrosis

Nutritional Rehabilitation in Cystic Fibrosis

Cystic fibrosis and fat malabsorption: Pathophysiology of the cystic fibrosis gastrointestinal tract and the impact of highly effective CFTR modulator therapy

Cystic fibrosis in the year 2020: A disease with a new face

[STUDIES ON POLYENE FATTY ACIDS IN TUMORS AND TUMOR BEARING ANIMALS].

Precision medicine advances in cystic fibrosis: Exploring genetic pathways for targeted therapies

Anxiety Disorders: Treatable regardless of the Severity of Comorbid Alcohol Dependence

Nutritional status in the era of highly effective CFTR modulators

Exploring the complexity of cystic fibrosis (CF) and psychosocial wellbeing in the 2020s: Current and future challenges